GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Maccura Biotechnology Co Ltd (SZSE:300463) » Definitions » Gross Profit

Maccura Biotechnology Co (SZSE:300463) Gross Profit : ¥1,552 Mil (TTM As of Sep. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Maccura Biotechnology Co Gross Profit?

Maccura Biotechnology Co's gross profit for the three months ended in Sep. 2024 was ¥385 Mil. Maccura Biotechnology Co's gross profit for the trailing twelve months (TTM) ended in Sep. 2024 was ¥1,552 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. Maccura Biotechnology Co's gross profit for the three months ended in Sep. 2024 was ¥385 Mil. Maccura Biotechnology Co's Revenue for the three months ended in Sep. 2024 was ¥669 Mil. Therefore, Maccura Biotechnology Co's Gross Margin % for the quarter that ended in Sep. 2024 was 57.56%.

Maccura Biotechnology Co had a gross margin of 57.56% for the quarter that ended in Sep. 2024 => Durable competitive advantage

During the past 13 years, the highest Gross Margin % of Maccura Biotechnology Co was 59.25%. The lowest was 51.80%. And the median was 54.16%.


Maccura Biotechnology Co Gross Profit Historical Data

The historical data trend for Maccura Biotechnology Co's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Maccura Biotechnology Co Gross Profit Chart

Maccura Biotechnology Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Gross Profit
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,670.01 1,967.49 2,306.71 1,956.64 1,600.45

Maccura Biotechnology Co Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 424.86 438.57 353.87 375.11 384.93

Competitive Comparison of Maccura Biotechnology Co's Gross Profit

For the Diagnostics & Research subindustry, Maccura Biotechnology Co's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Maccura Biotechnology Co's Gross Profit Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Maccura Biotechnology Co's Gross Profit distribution charts can be found below:

* The bar in red indicates where Maccura Biotechnology Co's Gross Profit falls into.



Maccura Biotechnology Co Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

Maccura Biotechnology Co's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as

Gross Profit (A: Dec. 2023 )=Revenue - Cost of Goods Sold
=2895.77 - 1295.318
=1,600

Maccura Biotechnology Co's Gross Profit for the quarter that ended in Sep. 2024 is calculated as

Gross Profit (Q: Sep. 2024 )=Revenue - Cost of Goods Sold
=668.704 - 283.778
=385

Gross Profit for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥1,552 Mil.

Gross Profit is the numerator in the calculation of Gross Margin.

Maccura Biotechnology Co's Gross Margin % for the quarter that ended in Sep. 2024 is calculated as

Gross Margin % (Q: Sep. 2024 )=Gross Profit (Q: Sep. 2024 ) / Revenue (Q: Sep. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=385 / 668.704
=57.56 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


Maccura Biotechnology Co  (SZSE:300463) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

Maccura Biotechnology Co had a gross margin of 57.56% for the quarter that ended in Sep. 2024 => Durable competitive advantage


Maccura Biotechnology Co Gross Profit Related Terms

Thank you for viewing the detailed overview of Maccura Biotechnology Co's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


Maccura Biotechnology Co Business Description

Traded in Other Exchanges
N/A
Address
Number 8, 2nd Anhe Road, Hi-tech Zone, Chengdu, CHN, 611731
Maccura Biotechnology Co Ltd is a China-based in-vitro diagnostic (IVD) integration company engaged in the research and development, production and sales of IVD products. It is also engaged in the sales of foreign brands of in vitro diagnostic products as an agent. The company's developed product and technology development platforms cover clinical biochemistry, chemiluminescent immunoassay, rapid diagnosis, thrombosis, hemostasis, and molecular diagnosis.
Executives
Guo Lei Director
Wang Deng Ming Directors, executives
Wang Lin Supervisors
Wu Ming Jian Directors, executives
Shi Wei Directors, executives
Yang Hui Supervisors
Zhou Yue Guo Executives
Wang Zhen Executives
Yu Ping Executives
Zou Yuan Supervisors
Xu Sheng Guo Directors, executives
Liu Qi Lin Directors, executives
Chu Jian Jun Executives
Tang Yong Director
Xu Jin Song Executives

Maccura Biotechnology Co Headlines

No Headlines